CHMC_NASH-2021_FINAL
Loading viewer...
report
Format: PDF report
This report details the Phase 1b/2a study of BIO89-100, highlighting its efficacy in reducing liver fat and improving metabolic parameters in NASH patients.
Loading viewer...
report
Format: PDF report
This report details the Phase 1b/2a study of BIO89-100, highlighting its efficacy in reducing liver fat and improving metabolic parameters in NASH patients.
report
report
Northrop Grumman Corporation
report
ORIX Corporation
report
HSBC
report
Jaguar
